KRTX Stock Recent News
KRTX LATEST HEADLINES
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Troy Ignelzi, chief financial officer of Karuna Therapeutics, will participate in a fireside chat at the Jefferies 2022 London Healthcare Conference on Wednesday, November 16, 2022, at 3:50 p.m.
The biotech sector is down this year, but these two biopharmaceutical stocks have delivered strong returns.
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that data from the Phase 3 EMERGENT-2 trial of KarXT in schizophrenia will be shared at the 35th European College of Neuropsychopharmacology (ECNP) Congress, to be held October 15-18, 2022, in Vienna, Austria. A poster presentation and symposium will incl
Karuna produced excellent data from its phase 3 trial. They have a boatload of cash.
Karuna Therapeutics, Inc. (KRTX) reported earnings 30 days ago. What's next for the stock?
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will present at the following upcoming investor conferences: Citi's 17th Annual BioPharma Conference Date: Wednesday, September 7, 2022 Time: 9:40 a.m. ET 2022 Wells Fargo Healthcare Conference Date: Thursday, September 8, 2022 Time
While researching about Karuna Therapeutics Inc. ( KRTX , Financial), I liked what I read so I decided to take a small position in the Boston-based biopharmaceutical company. Here I will invoke a common refrain: “If I had only bought more.
Karuna Therapeutics (KRTX) is progressing well with its pipeline development. KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.
Though Karuna's (KRTX) earnings miss estimates, KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.
The biotech's psych med hit the mark in a late-stage trial.